ITM Reports Re-treatment and Dosimetry Data for 177Lu-Edotreotide
BOSTON, Mass. — September 27, 2026 ITM Isotope Technologies Munich SE and Lumara Bio announced new real-world re-treatment and...
Targeted Radiotherapy
Advertisement
Actinium Advances Actimab-A With Manufacturing Expansion
New York, United States, August 14, 2026 Actinium Pharmaceuticals, Inc. announced new intellectual property and manufacturing developments supporting its...
ITM Receives FDA Complete Response Letter for ITM-11
Garching/Munich, Germany and Princeton, New Jersey, August 10, 2026 ITM Isotope Technologies Munich SE (ITM) announced that the U.S....
Cellectar Publishes Phase 1 Iopofosine Data
FLORHAM PARK, N.J., July 15, 2026 Cellectar Biosciences announced the publication of results from its Phase 1 dose-escalation study...
Niowave and Ratio Partner to Advance Actinium-225 Supply
LANSING, Mich. and BOSTON, Mass., June 16, 2026 Niowave, Inc. and Ratio Therapeutics Inc. have entered into a strategic...
Advertisements
Actinium Strengthens IP Portfolio for Radiotherapy Programs
NEW YORK, May 29, 2026 Actinium Pharmaceuticals, Inc. has announced the receipt of two patent allowances from the Canadian...
Advertisement
